explore -WSS

explore

author：comprehensive 2025-09-30 18:42:59 - browse：39

Powdered ibogaine against a white background. — Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Startling documents reveal new facets of Sacklers' opioid empire

explore

hotspot

WSS

Akili, maker of video game for ADHD, to be acquired for 34 million

Diversity in medical illustrations gets boost from Chidiebere Ibe

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

How to make Best Hospitals ratings actually useful for patients

Neuroscience startup Neumora files for IPO

iTeos Therapeutics debuts first data on TIGIT

focus

explore

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Health insurers say they are turning to AI to cut costs, improve care

Medical leaders decry Supreme Court decision on affirmative action

Health insurers say they are turning to AI to cut costs, improve care

Duchenne breakthrough therapy leaves behind pioneering families

What do new weight loss drugs mean for bariatric surgery?

Wildfire smoke exposes gaps in outdoor worker protections

Report: NIH

Activists slam private health insurers over coverage restrictions

Apellis safety probe of eye disease drug centers on injection needle

entertainment

Appeals court upholds limits to abortion pill

How a symptom of dementia informs our understanding of creativity

Akili, maker of video game for ADHD, to be acquired for 34 million

iTeos Therapeutics debuts first data on TIGIT

Stigma and the return of syphilis

Startling documents reveal new facets of Sacklers' opioid empire

knowledge

explore

hotspot

hotspot